Iberdomide to treat intermediate or high-risk smoldering myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have intermediate- or high-risk smoldering multiple myeloma diagnosed within the last 5 years
- Your tests fit at least one risk pattern: high marrow plasma cells, an abnormal light-chain ratio, or a higher monoclonal protein level
- Your blood counts and organs are strong enough: low infection risk (ANC), enough hemoglobin, and enough platelets
- Your kidney and liver tests are within limits, and your heart pumping strength (ejection fraction) is at least 40%
- You are well enough to travel for visits: performance status 0 to 2
- If you could become pregnant, you must meet strict pregnancy testing and contraception rules
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 3 trial studies whether lenalidomide plus dexamethasone can prevent or delay progression of “high-risk smoldering” multiple myeloma, and whether adding daratumumab improves outcomes. It’s meant for people who are not yet showing symptoms, but whose lab and scan results suggest higher risk.
This trial is testing a combination of two drugs, isatuximab and iberdomide, to help people with high-risk smoldering myeloma avoid progressing to active multiple myeloma. It aims to see if this immunotherapy approach can delay or prevent the need for stronger treatments.
This Phase 2 study tests a treatment approach for adults with active multiple myeloma (MM) or a high/intermediate-risk “smoldering” MM that hasn’t been treated yet. It may help by trying to control the disease earlier or more effectively, depending on what the trial drug(s) do.
This trial studies a precision approach to treat people with high-risk smoldering myeloma (a condition that can turn into active myeloma). The goal is to see whether the treatment can slow or prevent progression and improve outcomes.
This Phase 2 trial tests a combination of medicines (iberdomide, bortezomib, dexamethasone, and adding isatuximab) for people with newly diagnosed multiple myeloma who cannot have a transplant. The goal is to improve disease control while checking safety in older adults who can take pills and attend frequent visits.
This Phase 1 trial tests belantamab mafodotin, a cancer medicine, in people with high-risk smoldering multiple myeloma to see how safe it is and whether it may shrink or control the disease. Because it’s an early-stage study, you would be closely monitored and treated with one main study drug.
Hear when a new Smoldering Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.